$pali
Palisade Bio advances PALI-2108 for IBD, with Phase [--] IND submission planned for early [----]. Insider buying and abstract publication fuel positive sentiment amidst broader market speculation.
About $pali
Palisade Bio is a biotechnology company focused on developing treatments for inflammatory bowel disease (IBD).
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Month: [-------] -82%
[--] Months: [---------] +468%
[--] Year: [---------] +108%
1-Year High: [-------] on 2025-10-06
1-Year Low: [--] on 2025-05-24
Engagements by network (24h): X: [-----] Reddit: [--] YouTube: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [-----] on 2025-10-06
1-Year Low: [--] on 2025-06-05
Mentions by network (24h): X: [--] Reddit: [--] YouTube: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $pali in the last [--] hours which is down 8.70% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-10-06
1-Year Low: [--] on 2025-06-05
The most influential creators that mention $pali in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @HHSGov | [--] | [---] | [--] | [-----] |
| @DSAkdag | [--] | [------] | [--] | [-----] |
| @HFbho39211 | [--] | [--] | [--] | [---] |
| @seedy19tron | [--] | [------] | [--] | [---] |
| @mariam507333959 | [--] | [--] | [--] | [--] |
| @rynltmymy873300 | [--] | [--] | [--] | [--] |
| @ayasalmny | [--] | [--] | [--] | [--] |
| @mariostario2019 | [--] | [--] | [--] | [--] |
| @Tradingfast44 | [--] | [---] | [--] | [--] |
| @GIMedOnc | [--] | [-------] | [--] | [--] |
Sentiment: 67%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 67%
Daily Average: 81%
[--] Month: 78% +34%
[--] Months: 78% -22%
[--] Year: 78% -22%
1-Year High: 100% on 2025-02-17
1-Year Low: 22% on 2025-06-12
Most Supportive Themes:
- Clinical Development and IND Submission: (38%) Palisade Bio's PALI-2108 is progressing towards Phase [--] development for IBD, with a Phase [--] UC IND submission anticipated in early [----].
- Insider Buying and Retesting: (25%) Discussions highlight insider buying by a director and stock retesting, suggesting potential positive market signals.
- Abstract Publication: (13%) The release of a PK profile, safety, and summary abstract for PALI-2108 marks a significant milestone in the company's R&D efforts.
Most Critical Themes:
- Breakdown Concerns and Buyout Delays: (13%) Concerns exist regarding potential stock breakdowns and possible delays in buyouts for related entities, indicating a cautious outlook.
- General Stock Mentions and Speculation: (13%) Numerous posts mention $PALI alongside many other tickers, suggesting broad market speculation rather than focused interest.
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing